Chemical, Biological, Radiological and Nuclear Advance Defense Enabling Network and Clinical Capability (CADENCC)

The Department of the Army, via its Capability Program Executive for CBRN Defense and Joint Project Lead Enabling Technologies, seeks proposals to develop the Chemical, Biological, Radiological and Nuclear Advance Defense Enabling Network and Clinical Capability (CADENCC). The effort will create an enabling infrastructure that accelerates Phase I/II clinical trial start‑up for CBRN medical countermeasures (pre‑exposure prophylaxis, post‑exposure prophylaxis, and early‑treatment products), implements master protocols, leverages decentralized trial technologies, and establishes a pre‑positioned network of clinical sites to support rapid response to CBRN threats. The award will be a prototype agreement under Other Transaction Authority (OTA) with potential follow‑on production contracts. • Develop a network and clinical capability to speed CBRN medical countermeasure trials. • Implement master protocols and decentralized trial technologies for data collection and analysis. • Establish a pre‑positioned clinical trial site network for rapid deployment. • Conduct Phase I/II trials for PrEP, PEP, and early‑treatment products, possibly under the Animal Rule. • Prototype work funded under 10 USC 4022 OTA; follow‑on production contracts may be awarded. • Proposals limited to 10 pages (excluding cover, ROM, WBS); submission deadline 17 Sep 2026, 1500 hrs. • Evaluation criteria include technical merit, military relevance, TRL ≥ 4, regulatory compliance, key personnel, facilities, cost/price, and past performance.